Abstract
Acute myeloid leukemia is still the most feared haematological malignancy, Treatment results improved a lot during the past 35 years. This improvement is due to more agressive chemotherapeutic protocolls, better supportive therapy as well as in a certain cases to the use of stem cell transplantation. The development of monoclonal antibodies offers a targeted approach in the treatment, their efficacy can be improved with the addition of cytostatic drugs or radioisotopes. The CD33 antigen, expressed on the surface of myeloid blasts is a suitable target. Application of the non-conjugated anti-CD33 monoclonal antibody, lintuzumab or of the anti-CD33 monoclonal antibody conjugated with a toxin, gemtuzumab ozogamicin (GO) result in survival advantage in elderly patients with AML In the last decade GO has been applied in several combinations both in elderly and in young patients, in the primary as well as in the relapsed setting. Experience with treatment using monoclonal antibodies (anti CD33, antiCD45, anti CD66) combined with radioisotopes as part of conditioning treatment before stem cell transplantation is also growing. The development of new diagnostic possibilities and new knowledge on molecular genetic abnormalities in the background of the individual AML subtypes open new perspectives in drug development. Real success still remains to be awaited.
| Original language | Hungarian |
|---|---|
| Pages (from-to) | 205-210 |
| Number of pages | 6 |
| Journal | Orvoskepzes |
| Volume | 84 |
| Issue number | 3 |
| Publication status | Published - 2009 |
Fingerprint
Keywords
- Acute myeloid leukemia
- Gemtuzumab ozogamicin
- Monoclonal antibody
- Radio-immunotherapy
ASJC Scopus subject areas
- Medicine(all)
Cite this
A monoklonális antitestkezelés lehetoségei és korlátai heveny myeloid leukaemiában. / Anikó, Fodor; Demeter, J.
In: Orvoskepzes, Vol. 84, No. 3, 2009, p. 205-210.Research output: Article
}
TY - JOUR
T1 - A monoklonális antitestkezelés lehetoségei és korlátai heveny myeloid leukaemiában
AU - Anikó, Fodor
AU - Demeter, J.
PY - 2009
Y1 - 2009
N2 - Acute myeloid leukemia is still the most feared haematological malignancy, Treatment results improved a lot during the past 35 years. This improvement is due to more agressive chemotherapeutic protocolls, better supportive therapy as well as in a certain cases to the use of stem cell transplantation. The development of monoclonal antibodies offers a targeted approach in the treatment, their efficacy can be improved with the addition of cytostatic drugs or radioisotopes. The CD33 antigen, expressed on the surface of myeloid blasts is a suitable target. Application of the non-conjugated anti-CD33 monoclonal antibody, lintuzumab or of the anti-CD33 monoclonal antibody conjugated with a toxin, gemtuzumab ozogamicin (GO) result in survival advantage in elderly patients with AML In the last decade GO has been applied in several combinations both in elderly and in young patients, in the primary as well as in the relapsed setting. Experience with treatment using monoclonal antibodies (anti CD33, antiCD45, anti CD66) combined with radioisotopes as part of conditioning treatment before stem cell transplantation is also growing. The development of new diagnostic possibilities and new knowledge on molecular genetic abnormalities in the background of the individual AML subtypes open new perspectives in drug development. Real success still remains to be awaited.
AB - Acute myeloid leukemia is still the most feared haematological malignancy, Treatment results improved a lot during the past 35 years. This improvement is due to more agressive chemotherapeutic protocolls, better supportive therapy as well as in a certain cases to the use of stem cell transplantation. The development of monoclonal antibodies offers a targeted approach in the treatment, their efficacy can be improved with the addition of cytostatic drugs or radioisotopes. The CD33 antigen, expressed on the surface of myeloid blasts is a suitable target. Application of the non-conjugated anti-CD33 monoclonal antibody, lintuzumab or of the anti-CD33 monoclonal antibody conjugated with a toxin, gemtuzumab ozogamicin (GO) result in survival advantage in elderly patients with AML In the last decade GO has been applied in several combinations both in elderly and in young patients, in the primary as well as in the relapsed setting. Experience with treatment using monoclonal antibodies (anti CD33, antiCD45, anti CD66) combined with radioisotopes as part of conditioning treatment before stem cell transplantation is also growing. The development of new diagnostic possibilities and new knowledge on molecular genetic abnormalities in the background of the individual AML subtypes open new perspectives in drug development. Real success still remains to be awaited.
KW - Acute myeloid leukemia
KW - Gemtuzumab ozogamicin
KW - Monoclonal antibody
KW - Radio-immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=82455216852&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82455216852&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:82455216852
VL - 84
SP - 205
EP - 210
JO - Orvoskepzes
JF - Orvoskepzes
SN - 0030-6037
IS - 3
ER -